IRCT20221102056378N1招募中3 期
Evaluating the effects of empagliflozin in preventing myocardial damage in patients undergoing percutaneous coronary intervention: a double-blind randomized clinical trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Age 18-80 years
- •Ischemic heart diseases patients
- •candidate for angioplasty and stentstent insertion
- •Filling of consent form
排除标准
- •History of infarction
- •History of open heart surgery in the last 3 months
- •Renal dysfunction
- •Failed History of Coronary Angioplasty
- •cardiogenic shock
- •Liver failure
- •Autoimmune disease
- •History of serious allergy to empagliflozin
- •Inability in filling and understanding of the consent form
研究者
相似试验
招募中
2 期
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgeryAtrial fibrillation after heart surgery.Paroxysmal atrial fibrillationIRCT20120520009801N9Mashhad University of Medical Sciences160
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
已完成
1 期
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138